Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 2028-2036

  Yao, Kathy ^a   Lee, Eun Sook ^a,b   Bentrem, David J ^a   England, Gale ^a   Schafer, Jennifer I MacGregor ^a   O'Regan, Ruth M ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESISTANCE; MOUSE; NONHUMAN; NUDE MOUSE; POINT MUTATION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; RECEPTORS, ESTROGEN; TAMOXIFEN; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034066141     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 351: 1451-1467, 1998.
2. Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerjam, D. L., Wolmark, N., Constantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., Deschenes, L., Dimitrov, N. V., Margolese, R. G., Robidoux, A., Shibata, H., Terz, J., Paterson, A. H. G., Feldman, M. I., Farrar, W., Evans, J., and Lickley, L. Five years versus more than 5 years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor positive tumors. J. Natl. Cancer Inst., 88: 1529-1542, 1996.
3. Canney, P. A., Griffiths, T., Latief, T. N., and Priestman, T. J. Clinical significance of tamoxifen withdrawal response. Lancet, i: 36, 1987.
4. Howell, A., Dodwell, D. J., Anderson, H., and Redford, J. Response after withdrawal of tamoxifen and progesterone in advanced breast cancer. Ann. Oncol., 3: 611-617, 1992.
5. Gottardis, M. M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long term antiestrogen administration. Cancer Res., 48: 5183-5187, 1988.
6. Osborne, C. K., Coronado, E. B., and Robinson, J. P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol., 23: 1189-1196, 1987.
7. Wolf, D. M., and Jordan, V. C. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. In: H. J. Senn, A. Goldhirsch, and R. Gelber (eds.), Recent Results in Cancer Research, Vol. 127, pp. 22-27. Heidelberg: Springer-Verlag, 1993.
8. Wolf, D. M., and Jordan, V. C. Characterization of tamoxifen-stimulated MCF-7 tumor variants growth in athymic mice. Breast Cancer Res. Treat., 31: 11-27, 1994.
9. Wolf, D. M., and Jordan, V. C. The estrogen receptor from a tamoxifen-stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat., 31: 129-138, 1994.
10. Levenson, A. S., Tonetti, D. A., and Jordan, V. C. The oestrogen like effect of 4-hydroxytamoxifen on induction of transforming growth factor α mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Br. J. Cancer, 77: 1812-1819, 1998.
11. Gottardis, M. M., Robinson, S. P., and Jordan, V. C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J. Steroid Biochem., 30: 311-314, 1988.
12. Iino, Y., Wolf, D. M., Langan-Fahey, S. M., Johnson, D. A., Ricchio, M., Thompson, M. E., and Jordan, V. C. Reversible control of oestradiol-stimulated growth of MCF-7 tumors by tamoxifen in the athymic mouse. Br. J. Cancer, 64: 1019-1024, 1991.
13. O'Regan, R. M., Cisneros, A., England, G. M., MacGregor, J. I., Muenzner, H. D., Assikis, V. J., Bilimoria, M. M., Piette, M., Dragan, Y. P., Pitot, H. C., Chatterton, R., and Jordan, V. C. Effects of antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Natl. Cancer Inst., 90: 1552-1558, 1998.
14. Orita, M., Suzuki, Y., Sekiya, T., and Hakashi, K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5: 874-879, 1989.
15. Orita, M., Iwahana, H., Kanasawa, H., Hayashi, K., and Sekiya, K. Detection of polymorphisms of human DNA by gel electrophoresis as single-stranded conformation polymorphisms. Proc. Natl. Acad. Sci. USA, 86: 2766-2770, 1989.
16. Bilimoria, M. M., Assikis, V. J., Muenzner, H. D., Wolf, D. M., Satyaswaroop, P. G., and Jordan, V. C. An analysis of tamoxifen stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor. J. Steroid Biochem. Mol. Biol., 58: 479-488, 1996.
17. Jordan, V. C., Fritz, N. F., Langan-Fahey, S., Thompson, M., and Tormey, D. C. Alteration of endocrine parameters in premenopausal women with breast cancer during long term adjuvant therapy with tamoxifen as a single agent. J. Natl. Cancer Inst., 83: 1488-1491, 1991.
18. Langan-Fahey, S. M., Tormey, D. C., and Jordan, V. C. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer, 26: 883-888, 1990.
19. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G., and Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res., 48: 812-815, 1988.
20. Ingle, J. N., Ahmann, D. L., Green, S. J., Edmonson, J. H., Bisel, H. F., Kvols, L. K., Nichols, W. C., Creagan, E. T., Hahn, R. G., Rubin, J., and Frytak, S. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N. Engl. J. Med., 304: 16-21, 1981.
21. Kennedy, B. J., and Nathanson, I. T. Effect of intensive sex steroid hormone therapy in advanced breast cancer. J. Am. Med. Assoc., 152: 1135-1141, 1953.
22. Ostrowski, M. J., and Jackson, A. W. Polyestradiol phosphate: a preliminary evaluation of its effect on breast carcinoma. Cancer Treat. Rep., 63: 1803-1807, 1979.
23. Carter, A. C., Sedransk, N., Kelley, R. M., Ansfield, F. J., Ravdin, R. G., Talley, R. W., and Potter, N. R. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. J. Am. Med. Assoc., 237: 2079-2080, 1977.
24. Beex, L., Pieters, G., Smals, A., Koenders, A., Benraad, T., and Kloppenborg, P. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat. Rep., 65: 179-185, 1981.
25. Matelski, H., Greene, R., Huberman, M., Lokich, J., and Zipoli, T. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am. J. Clin. Oncol., 8: 128-133, 1985.
26. Brunner, N., Spang-Thomsen, M., and Cullen, K. The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer. Breast Cancer Res. Treat., 39: 87-92, 1996.
27. Brunner, N., Spang-Thomsen, M., Vindelov, L., and Nielsen, A. Effect of 17β-oestradiol on growth curves and flow cytometric DNA distribution of two human breast carcinomas grown in nude mice. Br. J. Cancer, 47: 641-647, 1983.
28. Brunner, N., Bastert, G. B., Poulsen, H. S., Spang-Thomsen, M., Engelholm, S. A., Vindelov, L., Nielsen, A., Tommerup, N., and Elling, F. Characterization of the T61 human breast carcinoma established in nude mice. Eur. J. Cancer Clin. Oncol., 21: 833-843, 1985.
29. Brunner, N., Spang-Thomsen, M., Vindelov, L., Nielsen, A., Engelholm, S. A., and Svenstrup, B. Dose-dependent effect of 17β estradiol determined by growth curves and flow cytometric DNA analysis of a human breast carcinoma (T61) grown in nude mice. Exp. Cell Biol., 53: 220-232, 1985.
30. Soule, H. D., Vazquez, J., Long, A., Albert, S., and Brennan, M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst., 51: 1409-1416, 1973.
31. Sawka, C. A., Pritchard, K. I., Paterson, A. H., Sutherland, D. J., Thomson, D. B., Shelley, W. E., Myers, R. E., Mobbs, B. G., Malkin, A., and Meakin, J. W. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res., 46: 3152-3156, 1986.
32. Jonat, W. Luteinizing hormone-releasing hormone analogues-the rationale for adjuvant use in premenopausal women with early breast cancer. Br. J. Cancer, 78: 5-8, 1998.
33. Boccardo, F., Blamey, R. W., Klijn, T., Tominaga, T., Duchateau, L., and Sylvester, R. LHRH-agonist + tamoxifen versus LHRH agonist alone in premenopausal women with advanced breast cancer: results of a meta analysis of four trials. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 18: 110, 1999.
34. Stoll, B. A. Palliation by castration or by hormone administration. In: B. A. Stoll (ed.), Breast Cancer Management, pp. 133-146. London: William Heineman, 1977.
35. Lee, E-S., Horiguchi, J., Liu, H., Takei, H., and Jordan, V. C. Regulation of angiogenesis in tamoxifen-stimulated breast tumors by the pure antiestrogen ICI182,780. Proc. Am. Assoc. Cancer Res., 41: 26, 2000.
36. Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., and Gustafsson, J. A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA, 93: 5925-5930, 1996.
37. McInerney, E. M., Weis, K. E., Sun, J., Mosselman, S., and Katzenellenbogen, B. S. Transcription activation by the human estrogen receptor subtype β (ER β) studied with ER β and ER α receptor chimeras. Endocrinology, 139: 4513-4522, 1998.
38. Hall, J. M., and McDonnell, D. P. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology, 140: 5566-5578, 1999.
39. Brzozowski, A. M., Pike, A., and Dauter, Z. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond.), 389: 753-758, 1997.
40. Pike, A. Brzozowski, A. M., Hubbard, R. E., Bonn, T., Thorsell, A., Engstrom, O., Ljunggren, J., Gustafsson, J., and Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J., 18: 4608-4618, 1999.
41. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S., and Gustafsson, J. A. Comparison of ligand binding specificity and transcript tissue distribution of estrogen receptor α and β. Endocrinology, 138: 863-870, 1997.
42. Barkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J. A., and Nilsson, S. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol. Pharmacol., 54: 105-112, 1998.
43. Paech, K., Webb, P., Kuiper, G., Nilsson, S., Gustafsson, J. A., Kushner, P. J., and Scanlan, T. S. Differential ligand activation of estrogen receptors ERα and ERβ at AP-1 sites. Science (Washington DC). 277: 1508-1510, 1997.
44. Webb, P., Lopez, G. N., Uht, R. M., and Kushner, P. J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol., 9: 443-456, 1995.
45. Webb, P., Nguyen, P., Valentine, C., Lopez, G. N., Kwok, G. R., McInerney, E., Katzenellenbogen, B. S., Enmark, E., Gustafsson, J. A., Nilsson, S., and Kushner, P. J. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol. Endocrinol., 13: 1672-1685, 1999.
46. Howell, A., DeFriend, D. J., Robertson, J., Blamey, R., and Walton, P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345: 989-990, 1995.
47. Howell, A., DeFriend, D. J., Robertson, J. F., Blamey, R. W., Anderson, L., Anderson, E., Sutcliffe, F. A., and Walton, P. Pharmaco-kinetics, pharmacological and antitumor effects of the specific antiestrogen ICI 182780 in women with advanced breast cancer. Br. J. Cancer, 74: 300-308, 1996.